However, in ovarian cancer, overexpression of FTO reduces m6A levels and mRNA transcript stability which inhibits the hydrolysis of the second messenger cAMP mediated by two phosphodiesterases, PDE1C (phosphodiesterases 1C) and PDE4B (phosphodiesterases 4B). Here, PDE1C is linked to ovarian cancer.